XHANCE

XHANCE uses an Optinose Exhalation Delivery System (EDS) that is designed to deliver medication1,2:

  • High and deep in the nasal passages
  • To regions where nasal polyps originate and sinuses drain and ventilate
Scroll down to explore reasons to prescribe XHANCE.

Chronic inflammation associated with nasal polyposis is generally high and deep and is difficult to reach

The ostiomeatal complex (OMC) is a region where nasal polyps usually originate and through which most sinuses drain and ventilate.3-6 The complexity of the nasal anatomy makes it difficult to deliver medication into the OMC.3-6
Learn more

XHANCE is designed to deposit medication deep in the nasal passages

XHANCE uses an Optinose Exhalation Delivery System (EDS) that is designed to deliver medication high and deep in the nasal passages to regions where nasal polyps originate and sinuses drain and ventilate.1-6
Learn more

Improvement in all 4 defining symptoms and reduction in nasal polyp grade

  • Patients using XHANCE reported improvement in congestion and other defining nasal symptoms1,2
  • XHANCE significantly reduced bilateral polyp grade, with some patients achieving total polyp elimination1,2

Learn more

Prescribing and administration of XHANCE is simple

  • > 90% of patients in clinical trials considered XHANCE easy to use2
  • The recommended dosage for XHANCE is 1 spray per nostril twice daily
  • XHANCE is also approved for 2 sprays per nostril twice daily

Learn more

References:
  1. Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2017.
  2. Data on file. OptiNose US, Inc.
  3. Zhong C, Jiang Z, Zhang X. Effect of distribution of nasal polyps in ostiomeatal complex on long-term outcomes after endoscopic surgery. Eur Arch Otorhinolaryngol. 2015;272(12):3757-3762.
  4. Larsen PL, Tos M. Origin of nasal polyps: an endoscopic autopsy study. Laryngoscope. 2004;114(4):710-719.
  5. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42-62.
  6. Liang J, Lane AP. Topical drug delivery for chronic rhinosinusitis. Curr Otorhinolaryngol Rep. 2013;1(1):51-60.